Abstract
The in-vitro activity of BMY 28142, a new α-methoxyimino aminothiazolyl cephalosporin, was determined by microdilution broth techniques. The agent demonstrated excellent activity against recent clinical Enterobacteriaceae isolates with a 90% minimum inhibitory concentration (MIC90) of 0·25 mg/l or less for all but one species tested. BMY 28142 inhibited all Pseudomonas aeruginosa strains tested (MIC90=8·0 mg/l) as well as most other non-fermentative bacteria studied. Methicillin-susceptible Staphylococcus aureus were susceptible to BMY 28142 with MIC90=4·0 mg/l, while methicillin-resistant strains were generally resistant (MIC range 8->32 mg/l).
Original language | English (US) |
---|---|
Pages (from-to) | 463-468 |
Number of pages | 6 |
Journal | Journal of Antimicrobial Chemotherapy |
Volume | 16 |
Issue number | 4 |
DOIs | |
State | Published - Oct 1985 |
ASJC Scopus subject areas
- Pharmacology
- Microbiology (medical)
- Infectious Diseases
- Pharmacology (medical)